LCS
GILD icon

Levin Capital Strategies’s Gilead Sciences GILD Stock Holding History

Levin Capital Strategies’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,000
Closed -$291K – 369
2020
Q4 		$291K Buy
+5,000
New +$302K 0.03% 216

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Levin Capital Strategies's GILD Position: Q1 2022 in Review

Levin Capital Strategies sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 2,800 shares — an estimated $203K sold.

Levin Capital Strategies first reported a position in GILD in Q4 2014 and held it in 8 quarters. The position peaked at $67.2M in Q4 2014. 1,601 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

  • Levin Capital Strategies reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
  • Levin Capital Strategies sold 2,800 Gilead Sciences shares in Q1 2022, an estimated $203K.
  • Levin Capital Strategies first reported a position in Gilead Sciences in Q4 2014 and held it in 8 quarters.
  • Levin Capital Strategies's Gilead Sciences position peaked at $67.2M in Q4 2014.
  • 1,601 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Levin Capital Strategies's 13F filing for Q1 2022, filed 2 May 2022.